The study looked at the following variants of concern: alpha, beta, gamma, delta, epsilon and iota.
Researchers tested sera from a random sample of eight volunteers in three age groups: 18-55, 55-70, and 71 and older. All participants had samples available for four timepoints: four weeks after the first dose, two weeks after the second dose, 3 months after the second dose and six months after the second dose.
“These data support the durable efficacy of 93 percent seen with the Moderna COVID-19 vaccine through six months. We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Moderna CEO Stéphane Bancel said in a news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
